 The more intense native liver and pancreatic uptake seen with this agent would be expected to limit disease detection in those organs.FACBC has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron.Axumin is marketed by Blue Earth Diagnostics, Ltd., United Kingdom.